Phathom Pharmaceuticals (PHAT) News Today $6.39 -0.16 (-2.44%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Simplify Asset Management Inc. Grows Holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)Simplify Asset Management Inc. lifted its position in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 11.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 581,9March 24 at 6:18 AM | marketbeat.comPhathom Pharmaceuticals price target lowered to $13 from $17 at JefferiesMarch 20, 2025 | markets.businessinsider.comPhathom Pharmaceuticals director buys $44.2K shares of common stockMarch 17, 2025 | markets.businessinsider.comThe Goldman Sachs Group Issues Pessimistic Forecast for Phathom Pharmaceuticals (NASDAQ:PHAT) Stock PriceThe Goldman Sachs Group cut their price objective on shares of Phathom Pharmaceuticals from $18.00 to $12.00 and set a "neutral" rating for the company in a research report on Monday.March 11, 2025 | marketbeat.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Consensus Recommendation of "Buy" from AnalystsShares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report) have earned a consensus rating of "Buy" from the six ratings firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating, four have assigned a buy rating and oMarch 11, 2025 | marketbeat.comPhathom Pharmaceuticals’ Earnings Call: Growth and ChallengesMarch 10, 2025 | tipranks.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q4 2024 Earnings Call TranscriptMarch 10, 2025 | msn.comPhathom Pharmaceuticals, Inc. (PHAT) Q4 2024 Earnings Call TranscriptMarch 9, 2025 | seekingalpha.comPhathom Pharmaceuticals (NASDAQ:PHAT) Earns Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $28.00 target price on shares of Phathom Pharmaceuticals in a report on Friday.March 8, 2025 | marketbeat.comPhathom Pharmaceuticals price target lowered to $12 from $18 at Goldman SachsMarch 7, 2025 | markets.businessinsider.comPhathom Pharmaceuticals Full Year 2024 Earnings: Beats ExpectationsMarch 7, 2025 | uk.finance.yahoo.comPhathom Pharmaceuticals price target lowered to $18 from $28 at GuggenheimMarch 7, 2025 | markets.businessinsider.comPhathom Pharmaceuticals price target lowered to $19 from $27 at Craig-HallumMarch 7, 2025 | markets.businessinsider.comPhathom Pharmaceuticals Inc (PHAT) Q4 2024 Earnings Call Highlights: FDA Approval Boosts ...March 7, 2025 | finance.yahoo.comPhathom Pharmaceuticals' (PHAT) "Buy" Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and set a $28.00 price target on shares of Phathom Pharmaceuticals in a report on Thursday.March 7, 2025 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Releases Earnings Results, Beats Expectations By $0.41 EPSPhathom Pharmaceuticals (NASDAQ:PHAT - Get Free Report) announced its earnings results on Thursday. The company reported ($0.88) earnings per share for the quarter, beating the consensus estimate of ($1.29) by $0.41.March 7, 2025 | marketbeat.comPhathom Pharmaceuticals reports Q4 EPS ($1.05), consensus ($1.08)March 6, 2025 | markets.businessinsider.comPhathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 6, 2025 | globenewswire.comPhathom Pharmaceuticals (PHAT) Projected to Post Quarterly Earnings on ThursdayPhathom Pharmaceuticals (NASDAQ:PHAT) will be releasing earnings before the market opens on Thursday, March 6, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=669349)February 27, 2025 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Stock Rating Upgraded by Cantor FitzgeraldCantor Fitzgerald raised Phathom Pharmaceuticals to a "strong-buy" rating in a report on Tuesday.February 26, 2025 | marketbeat.com2 ‘Strong Buy’ Stocks Under $10 Set to Surge as Much as 331%February 25, 2025 | msn.comPhathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025February 24, 2025 | globenewswire.comPhathom Pharmaceuticals (NASDAQ:PHAT) Now Covered by Cantor FitzgeraldCantor Fitzgerald began coverage on Phathom Pharmaceuticals in a research report on Friday. They issued an "overweight" rating and a $23.00 price objective for the company.February 15, 2025 | marketbeat.comPhathom spikes as Cantor Fitzgerald bullish on IP claimsFebruary 14, 2025 | msn.comPhathom Pharmaceuticals initiated with an Overweight at Cantor FitzgeraldFebruary 14, 2025 | markets.businessinsider.comPhathom Pharmaceuticals initiated at Cantor Fitzgerald on ‘significant’ upsideFebruary 14, 2025 | markets.businessinsider.comPhathom Pharmaceuticals (PHAT) Gets a Buy from Stifel NicolausFebruary 10, 2025 | markets.businessinsider.comStifel maintains $28 target on Phathom Pharmaceuticals stockFebruary 8, 2025 | msn.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Holdings Boosted by Jennison Associates LLCJennison Associates LLC lifted its position in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 20.4% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 7,062,507 shares of the company's stock after acquiring an additional 1,196,118 sharesFebruary 4, 2025 | marketbeat.comPHAT stock touches 52-week low at $6.06 amid market challengesJanuary 31, 2025 | msn.comPhathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech ConferenceJanuary 29, 2025 | globenewswire.comPhathom Pharmaceuticals COO Nabulsi sells $51,956 in stockJanuary 24, 2025 | msn.comPhathom Pharmaceuticals CFO Molly Henderson sells shares worth $43,370January 24, 2025 | msn.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) CFO Molly Henderson Sells 6,583 SharesJanuary 24, 2025 | insidertrades.comInsider Selling: Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) CFO Sells 6,583 Shares of StockPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report) CFO Molly Henderson sold 6,583 shares of the firm's stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $6.59, for a total transaction of $43,381.97. Following the transaction, the chief financial officer now directly owns 93,546 shares of the company's stock, valued at approximately $616,468.14. This trade represents a 6.57 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.January 23, 2025 | marketbeat.comInsider Selling: Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) COO Sells 7,886 Shares of StockPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report) COO Azmi Nabulsi sold 7,886 shares of the business's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $6.59, for a total transaction of $51,968.74. Following the sale, the chief operating officer now directly owns 233,390 shares of the company's stock, valued at $1,538,040.10. This represents a 3.27 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.January 23, 2025 | marketbeat.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Insider Terrie Curran Sells 19,109 SharesPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report) insider Terrie Curran sold 19,109 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $6.59, for a total value of $125,928.31. Following the sale, the insider now directly owns 360,465 shares in the company, valued at $2,375,464.35. This trade represents a 5.03 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.January 23, 2025 | marketbeat.comPhathom Pharmaceuticals' (PHAT) Buy Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and issued a $28.00 target price on shares of Phathom Pharmaceuticals in a research note on Friday.January 10, 2025 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 6.9% - Here's What HappenedPhathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 6.9% - Should You Sell?January 2, 2025 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Trading 7.1% Higher - What's Next?Phathom Pharmaceuticals (NASDAQ:PHAT) Trading 7.1% Higher - Time to Buy?December 26, 2024 | marketbeat.comState Street Corp Raises Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)State Street Corp lifted its stake in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 17.5% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 922,788 shares of the company's stock after purchasinDecember 25, 2024 | marketbeat.comInsider Selling: Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) CFO Sells 1,291 Shares of StockPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report) CFO Molly Henderson sold 1,291 shares of the business's stock in a transaction that occurred on Thursday, December 19th. The shares were sold at an average price of $8.00, for a total value of $10,328.00. Following the completion of the sale, the chief financial officer now directly owns 98,156 shares in the company, valued at approximately $785,248. The trade was a 1.30 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.December 20, 2024 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 2% - What's Next?Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 2% - Here's What HappenedDecember 20, 2024 | marketbeat.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Director Acquires 12,500 Shares of StockDecember 17, 2024 | insidertrades.comPhathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap Up on Insider Buying ActivityPhathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap Up After Insider Buying ActivityDecember 16, 2024 | marketbeat.comFrank Karbe Acquires 12,500 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) StockPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report) Director Frank Karbe acquired 12,500 shares of the company's stock in a transaction that occurred on Friday, December 13th. The shares were acquired at an average cost of $7.93 per share, for a total transaction of $99,125.00. Following the completion of the transaction, the director now directly owns 57,000 shares of the company's stock, valued at $452,010. The trade was a 28.09 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link.December 16, 2024 | marketbeat.comPhathom Pharmaceuticals: Securing Long-term Exclusivity for Growth PotentialDecember 12, 2024 | markets.businessinsider.comPhathom Pharmaceuticals: Undervalued Opportunity with Strategic Moves for Extended ExclusivityDecember 12, 2024 | markets.businessinsider.comDo You Believe in the Growth Potential of Phathom Pharmaceuticals (PHAT)?December 12, 2024 | msn.comPhathom Pharmaceuticals' (PHAT) Buy Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $28.00 target price on shares of Phathom Pharmaceuticals in a research report on Thursday.December 12, 2024 | marketbeat.com Remove Ads Get Phathom Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAT and its competitors with MarketBeat's FREE daily newsletter. Email Address PHAT Media Mentions By Week PHAT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PHAT News Sentiment▼0.770.63▲Average Medical News Sentiment PHAT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PHAT Articles This Week▼23▲PHAT Articles Average Week Remove Ads Get Phathom Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Vera Therapeutics News Galapagos News Kiniksa Pharmaceuticals News Schrödinger News Ascentage Pharma Group International News IDEAYA Biosciences News Wave Life Sciences News Immunocore News ANI Pharmaceuticals News Dyne Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PHAT) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phathom Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phathom Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
